About Repligen Corporation

Repligen Corporation, founded in 1981, has transformed from a biopharmaceutical company to become a pure-play bioprocessing leader serving the rapidly growing biologics manufacturing industry. The company provides critical tools and technologies that enable efficient production of life-saving medicines. RGEN stock price has reflected strong growth as biologic drugs become increasingly important in treating diseases.

Led by CEO Tony Hunt, Repligen has executed a successful strategy of organic growth supplemented by strategic acquisitions to build a comprehensive bioprocessing portfolio. The management team's deep industry expertise and focus on innovation have positioned the company as a trusted partner to biopharmaceutical manufacturers. Leadership's vision for capturing the secular growth in biologics manufacturing has been instrumental in driving consistent performance and RGEN stock price appreciation.

Repligen operates by developing, manufacturing, and selling bioprocessing products including filtration systems, chromatography products, proteins, and process analytics tools used throughout biologic drug production. The company serves biopharmaceutical companies globally, benefiting from increasing biologics development, growing biosimilar production, and expansion of manufacturing capacity. With the biologics market continuing to expand, cell and gene therapy creating new bioprocessing demands, and Repligen's broad portfolio addressing critical manufacturing needs, RGEN offers investors exposure to the high-growth bioprocessing market with strong secular tailwinds from the ongoing shift toward biologic medicines.